Introduction
High levels of O 6 -alkylguanine-DNA alkyltransferase (OGAT) or loss of DNA-mismatch repair (MR) activity are associated with resistance to methylating agents. 1, 2 In the latter case, resistance is due to reduced MR-dependent activation of signal transduction pathways which ultimately lead to apoptosis. In fact, O 6 -methylguanine pairs either with thymine or cytosine to form mismatched substrates that trigger the intervention of MR. Futile attempts to find the complementary base for O 6 -methylguanine eventually lead to the formation of strand breaks and apoptosis. 3 In MR-proficient cells, resistance to methylating agents, due to high levels of OGAT, can be abrogated by depletion of OGAT activity using O 6 -benzylguanine, that is presently undergoing phase I studies. 4, 5 To date, there are no therapeutic strategies that can reverse resistance induced by functional loss of MR. Actually, MR deficiency is also associated with low-level resistance to other antineoplastic agents which do not methylate DNA, such as busulfan, platinum compounds, doxorubicin, etoposide and 6-thioguanine. 6 A functional MR is required for the maintenance of the genetic stability of DNA. Loss of its function leads to a mutator phenotype, characterized by a high rate of mutations throughout the genome. A consequence of the mutator phenotype is the generation of multiple replication errors in repetitive DNA sequences, resulting in microsatellite instability (MSI). Thus, the presence of MSI in tumor cells has been considered an indirect evidence of MR gene disruption. In hematological malignancies MSI and MR gene mutations are not as common as in solid tumors. Nevertheless, they have been described in lymphoid tumors and in acute myeloid leukemias secondary to previous chemotherapy or arising in elderly patients. [7] [8] [9] We recently demonstrated that MR-deficient leukemic cells can be rendered sensitive to the methylating agent temozolomide (TZM), when this agent is combined with poly(ADPribose) polymerase (PARP) inhibitors. 10, 11 Since PARP is a component of the base excision repair system (BER), we suggested that cytotoxic and apoptotic effects of TZM and PARP inhibitors in cells tolerant to O 6 -methylguanine, might be the consequence of reduced repair of other methyl lesions generated from TZM. N 3 -methyladenine (N 3 -MeA) and N 3 and N 7 -methylguanines are among the modified DNA bases, that induce the single-nucleotide replacement mediated by BER. The first step of the BER process is the excision of the modified base by damage-specific DNA glycosylases. This is followed by incision of the phosphodiester bond 5Ј to the lesion by an apurinic/apyrimidinic endonuclease. 12 The removal of the abasic residue generates a nucleotide gap, which is finally filled by the co-ordinate intervention of PARP, DNA polymerase ␤, X-ray repair cross-complementing 1 (XRCC1), and ligase I and III.
Although methylating agents react to some extent with DNA at all four bases, the adduct profile for each class of compounds is often different. For instance, in the case of TZM at least 70% of the methyl adducts are located at N 7 -guanine, 9% at N 3 -adenine and 5% at O 6 -guanine. 13 Moreover, the steady-state level of DNA adducts formed is dependent not only upon the rate of alkylation but also upon the efficiency of repair systems.
Even though N 7 -methylguanine is the most abundant adduct generated by methylating agents, it appears to have little or no lethal effects. 14 In contrast, unrepaired N 3 -MeA is an extremely toxic DNA lesion, that is capable of inhibiting DNA replication and of inducing apoptosis and chromosome aberrations. 15 In fact, 3-methylpurine DNA glycosylase (MPG)-deficient murine cells are highly sensitive to MeOSO 2 (CH 2 ) 2 -lexitropsin (Me-Lex). 15, 16 Moreover, the cytotoxicity of this agent is greatly enhanced in bacterial that cannot repair N 3 -MeA. 17 Me-Lex is a methyl sulfonate ester tethered to N-methylpyrrolecarboxamide dipeptide, which targets the minor groove of AT-rich DNA sequences. It almost exclusively produces N 3 -MeA (Ͼ99%), as demonstrated in previous studies in which DNA adducts from Me-Lex have been quantitated by treating genomic DNA or mammalian cells. 18, 19 In contrast to Me-Lex, the level of N 3 -MeA generated by TZM is extremely low and, consequently, in the presence of a functional BER system, this damaged base is rapidly repaired. Inhibition of PARP is likely to hamper the completion of BER process, which occurs after removal of the methylated base by MPG.
The aim of the present study is to investigate whether MRdeficient leukemic cells are susceptible to the cytotoxic effects of N 3 -MeA and whether PARP inhibition might increase chemosensitivity to this lesion. MR-deficient cells and Me-Lex provide an ideal model to clarify better the biological consequences deriving from the incomplete repair of N 3 -MeA, which would occur when a PARP inhibitor is combined either with Me-Lex or TZM. Furthermore, this model allows exploration of new pharmacological modalities to overcome tumor cell resistance to O 6 -methylating agents and possibly to other antineoplastic drugs.
Materials and methods

Cell line and culture conditions
The T lymphoblastic leukemia cell line Jurkat and the human colon cancer cell line HT-29 were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA). The human lymphoblastoid cell line MT-1 20 was a generous gift from WG Thilly (Massachusetts Institute of Technology, Cambridge, MA, USA). Both MT-1 and Jurkat are MR-deficient cell lines. 20, 21 Jurkat cells are p53-null since they harbor in their genome a mutated form of p53 gene, 22 whereas MT-1 are capable of inducing p53 upon treatment with DNA damaging agents. 3 Cell lines were cultured in RPMI-1640 (Gibco, Paisley, UK) supplemented with 10% fetal calf serum (Gibco), 2 mM L-glutamine, 100 units/ml penicillin and 100 g/ml streptomycin (Flow Laboratories, McLean, VA, USA), at 37°C in a 5% CO 2 humidified atmosphere.
Drugs
Me-Lex was prepared as previously described. 23 The PARP inhibitor 3-aminobenzamide (3-AB) was purchased from Sigma (St Louis, MO, USA). TZM was kindly provided by Shering Plough Research Institute (Kenilworth, NJ, USA). Drug stock solutions were prepared by dissolving Me-Lex in 95% ethanol (10 mM), TZM in dimethyl sulfoxide (100 mM) and 3-AB in RPMI-1640 (16 mM). The final concentration of dimethyl sulfoxide or ethanol in drug-treated cultures was always less than 0.5% (v/v) and did not contribute to toxicity (data not shown).
Drug treatment and cell growth evaluation
Cells were cultured in flasks (Falcon, Becton Dickinson Labware, Oxnard, CA, USA) at the concentration of 3 x 10 5 cells/ml. Inhibition of PARP was obtained by treating the cells with 4 mM 3-AB, a concentration which has been described as completely inhibiting PARP activity. 24 Me-Lex or TZM were added to cell cultures either alone or immediately after 3-AB addition, and it was used at concentrations ranging from 1.5 to 50 M and 62.5 to 250 M, respectively. Cells were then incubated at 37°C for 3 days and cell growth was evaluated, every 24 h, by counting viable cells in quadruplicate. Cell viability was determined by trypan blue dye exclusion. Cell line chemosensitivity to Me-Lex was evaluated in terms of IC 50 , ie the concentration of the drug expressed in M, capable of inhibiting cell growth by 50%. The IC 50 was calculated on the regression line in which the number of viable cells was plotted vs the drug concentration.
Assessment of apoptosis by flow cytometry analysis
Cells were harvested, washed with phosphate-buffered saline and fixed in 70% ethanol at −20°C for 18 h. After centrifugation, cells were resuspended in 1 ml of hypotonic solution containing 50 g/ml propidium iodide (PI; Sigma), 0.1% sodium citrate, 0.1% Triton-X, and 10 g/ml RNase (Boerhinger Mannheim, Milan, Italy), and incubated at 37°C in the dark, for 15 min. Data collection was gated utilizing forward light scatter and side light scatter to exclude cell debris and aggregates. PI fluorescence was measured on a linear scale using a FACSscan flow cytometer (Becton Dickinson, San Jose, CA, USA). Apoptotic cells are represented by a broad hypodiploid peak, which is easily distinguishable from the narrow peak of cells with diploid DNA content in the red fluorescence channel.
Analysis of chromosome aberrations
For chromosomal analysis, cell cultures were incubated for 2 h with 0.8 g/ml of colchicine (Sigma) before harvesting. Metaphase preparations were obtained according to standard techniques, treating cells first with a hypotonic solution (KCl 0.075 M) and then with a fixative mixture methanol/acetic acid (3/1). Air-dried slides were stained with 5% Giemsa in phosphate buffer.
Chromatid and chromosome breaks were evaluated by analyzing one hundred metaphases for each culture. Chromatid exchanges (tri-and tetra-radials) were counted as two chromatid breaks and chromosome exchanges (dicentric and translocations) as two chromosome breaks. The number of cells with aberrations was also calculated. For each slide the mitotic indexes (MI) (ie the percentage of dividing cells on 1000 nuclei examined), and the percentages of nuclei that appeared fragmented were also evaluated. Statistical analysis was performed using the normal standardized deviate as described. 25 
Western blotting
Cell lysates and samples for electrophoresis were prepared as previously described. 11 Eighty g of protein per sample were electrophoresed in 12% SDS-polyacrylamide mini-gels. Afterwards, proteins were transferred to nitrocellulose membranes (Schleicher & Schuell, Keene, NH, USA). Equal protein loading was visualized by Ponceau S staining. Filters were blocked with blocking buffer (Boehringer Mannheim) and incubated with the monoclonal antibody directed against p53 (PAb1801) (Oncogene, Cambridge, MA, USA). Immune-complexes were visualized using a chemiluminescence kit (Amersham International, Amersham, UK), according to the manufacturer's instructions. Filters were exposed to X-OMAT AR autoradiographic films (Kodak) for 10-45 s, depending on the intensity of the signal. Bidimensional densitometry of the blots was performed using an Imaging densitometer, GS-670 (BioRad, Richmond, CA, USA).
Measurement of MPG activity
MPG activity was assayed as previously described. 26 Tumor cells ( 10 7 ) were sonicated at 4°C in 0.5 ml buffer I (50 mM Tris-HCl, 3 mM dithiothreitol, and 2 mM EDTA, pH 8.3), with freshly added 1 mM 4-(2-aminoethyl)-benzene-sulfonyl fluoride hydrochloride. After removal of cell debris by centrifugation, supernatants were immediately tested for MPG activity. Various amounts of tumor cell extracts were incubated with 10 g (10 000 c.p.m.) of freshly dissolved calf thymus DNA methylated by N-3 H-methyl-N-nitrosourea (19 Ci/mmol; Amersham), in a total volume of 100 l of buffer II (20 mM Tris-HCl, 1 mM dithiothreitol, 60 mM NaCl, and 1 mM EDTA pH 8). After 1 h at 37°C, the reaction was stopped on ice by the addition of 30 l of 2 m NaCl containing 0.5 mg/ml calf thymus DNA and 1 mg/ml bovine serum albumin. DNA was ethanol-precipitated and samples were centrifuged at 10 000 g for 15 min. Three hundred l of the supernatants were transferred to a scintillation tube and counted. The MPG activity was determined for protein and time-limiting conditions and expressed as fmol of methyl groups released per 1 × 10 6 cells per hour.
Northern blot analysis
Total cellular RNA was extracted using the TriPure isolation reagent (Boehringer Mannheim). RNAs (15 g) were fractionated by electrophoresis on a formaldehyde-containing 1.2% agarose gel. The integrity of RNA was confirmed by RNA visualization, adding ethidium bromide to the RNA gel loading buffer. RNA was transferred to nylon membrane (Gene Screen Plus; NEN Life Science Products, Boston, MA, USA) and hybridized at 68°C for 1 h with a 32 P-labeled probe, using the QuickHyb hybridization solution (Stratagene, Cambridge, UK). Washing of the blots was performed according to the manufacturer's instructions. The blotted membrane was exposed to X-ray film at −80°C.
The DNA probe used for the detection of XRCC1 was obtained by polymerase chain reaction as previously described. 11 The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe, a 0.9 kb EcoRI fragment of the human GAPDH gene, was a generous gift from Dr R Dalla Favera (Department of Pathology, Columbia University, New York, NY, USA). Bidimensional densitometry of the blots was performed as described for Western blot analysis.
Results
Cytotoxic effects of Me-Lex, alone or combined with PARP inhibitor, in MR-deficient cells
In order to investigate whether MR-deficient leukemic cells are susceptible to cytotoxicity induced by N 3 -MeA, Jurkat or MT-1 cells were exposed to graded concentrations of Me-Lex Leukemia and cell growth was evaluated, at daily intervals, during 72 h of culture. Moreover, it was also explored whether the PARP inhibitor 3-AB might be capable of potentiating the cytotoxic effects of Me-Lex.
Treatment with Me-Lex alone inhibited the growth of Jurkat or MT-1 cells at different extents depending on the drug concentrations used (Figure 1) . Actually, Me-Lex induced a more pronounced growth inhibitory effect in MT-1 cells with respect to Jurkat cells. The IC 50 s of the drug for each cell line, calculated with the data of three independent experiments, were as follows: 7.6 ± 0.3 M (MT-1) and 13.8 ± 0.3 M (Jurkat) at 48 h, or 4 ± 0.1 M (MT-1) and 8.2 ± 0.2 M (Jurkat) at 72 h of culture.
When the drug was combined with the PARP inhibitor 3-AB, an increase of Me-Lex-mediated cytotoxicity was observed (Figure 2 ). This effect was more evident in both cell lines at 24 h after drug treatment and with the lowest drug concentrations (1.5 and 3.1 M).
Treatment with TZM alone (62.5-250 M) did not substantially affect the growth of Jurkat or MT-1 cells. In contrast, when the drug was associated with 3-AB a significant (P Ͻ 0.01) reduction of cell growth with respect to controls, was observed at all the drug concentrations tested, in both cell lines (Ref. 11, and data not shown).
PARP inhibition enhances chromosome aberrations induced by Me-Lex or TZM
Previous studies indicated that Me-Lex induces chromosome aberrations in murine embryonic stem (ES) cells. 15 Studies were performed to explore whether this agent also damaged chromosomes in human leukemic cell lines. Therefore, Jurkat and MT-1 cells were treated with graded concentrations of Me-Lex and metaphase cells were analyzed for the presence of chromosome aberrations. MT-1 cultures appeared to be more susceptible than Jurkat cells to the cytotoxic effect of the N 3 -methylating agent. The mitotic indexes of MT-1 cells were heavily depressed and to a higher extent than those of Jurkat cells. Therefore, in the case of MT-1 only cultures exposed to Me-Lex concentrations lower (ie 3.1 and 6.2 M) than those used for Jurkat cells could be analyzed.
In both cell lines all drug treatments, with only the exception of 3.1 M Me-Lex alone in MT-1 cells at 24 h, induced a significant (P Ͻ 0.01) number of aberrations (Figure 3) , compared with values found in untreated or in 3-AB-treated cultures. Moreover, chromosome damage was evident as early as 6 h after drug exposure (Figure 3) .
Addition of 3-AB to Me-Lex increased the clastogenic effect of the drug (Figure 3) . In fact, a significantly higher number of aberrations was found in the groups exposed to the drug combination with respect to that detected in groups treated with the single agent (Figure 3) . Actually, in the case of MT-1 cells statistically significant differences were observed only at 24 h. Moreover, in cells treated with 3-AB and Me-Lex the number of aberrant cells was significantly higher with respect to that of cells treated with Me-Lex alone (data not shown).
TZM treatment produced, in Jurkat cells, significant clastogenic effects only when associated with the PARP inhibitor (data not shown). No chromosome aberrations higher than those detectable in untreated controls, were found, instead, when Jurkat cells were exposed to 3-AB alone (data not shown). 
Analysis of apoptosis and p53 induction mediated by Me-Lex, alone or in combination with PARP inhibitor
In order to test whether Me-Lex might induce apoptosis in human MR-deficient cell lines, Jurkat and MT-1 cells were exposed to graded concentrations of Me-Lex, ranging from 3.1 M to 12.5 M. Apoptosis was evaluated, 24 h after drug exposure, measuring sub-G 1 DNA content by flow cytometry after staining of the cells with PI (Figure 4) . The results indicate that at 24 h Me-Lex induced apoptosis only in a limited percentage of Jurkat cells, but it was slightly more effective in MT-1 (Figure 4) . Moreover, treatment with 3-AB always increased the apoptotic effects of the drug (Figure 4) .
Morphological analysis of the nuclear apoptotic modifications occurring in treated cells was also performed. Fragmented nuclei were counted and the results were expressed as the fragmented nuclei ratio between drug-treated and untreated or 3-AB-treated groups. The results indicate that Jurkat cells treated with elevated Me-Lex concentrations (25 M and 50 M) in combination with 3-AB showed substantially higher levels of nuclear fragmentation compared to cells treated with Me-Lex alone, either at 6 h or at 24 h after treatment ( Figure 5 ).
DNA damage resulting from the presence of unrepaired N 3 -MeA or from MR-activation by O 6 -methylguanine is known to induce p53 expression. 3, 15 In the present model system we have investigated whether the failure of BER to complete the repair process due to PARP inhibition might induce p53 ( Figure 6 ). MT-1 cells, endowed with a wild-type p53, were exposed to Me-Lex (3.1 M and 6.2 M), alone or in combination with 3-AB, and levels of p53 protein were analyzed by Western blot. The results, illustrated in Figure 6 , indicated that Me-Lex either used as single agent or in combination induced p53 as early as 6 h after drug exposure. At the concentrations of 3.1 M, the expression of p53 was higher in cells treated with the drug combination than in cells treated with Me-Lex alone.
Analysis of MPG activity in Jurkat and MT-1 cells
We have investigated whether the higher susceptibility of MT-1 cells with respect to Jurkat cells might be at least in part due to low levels of MPG. The MPG activity in MT-1 cells was barely detectable (limit of detection is 5 fmol/10 6 cells/h), whereas Jurkat cell extracts showed a higher level of activity (49 fmol/10 6 cells/h). In these experimental conditions Jurkat cells showed a 1.6-fold lower activity than HT-29 cells (80 fmol/10 6 /h), in accordance with a previous report. 27 HT-29 cells were used as positive controls since they express high levels of MPG activity. 
Figure 6
Induction of p53 in MT-1 cells treated with Me-Lex, alone or combined with 3-AB. Western blot analysis of p53 protein levels was performed 6 h after exposure to Me-Lex or Me-Lex combined with PARP inhibitor. The ratio between the optical densities of groups treated with the drug combination and those treated with the single agent were: 1.1 and 1.96, at 6.2 M and 3.1 M, respectively. The data are representative of one out of two independent experiments with similar results.
Me-Lex treatment modulates XRCC1 gene transcript
We have previously demonstrated that treatment of Jurkat cells with TZM associated with 3-AB increased the expression of XRCC1 gene transcript, a component of BER complex. 11 Therefore, it was hypothesized that in cells tolerant to O 6 -methylguanine, this could be due to unrepaired strand breaks derived from the processing of methyl-adducts different from O 6 -methylguanine. In this study, we investigated whether modulation of XRCC1 gene transcript might occur after treatment with PARP inhibitor and a methylating agent which mainly generates N 3 -MeA adducts. Expression of XRCC1 after drug treatment of Jurkat cells changed upon drug treatment. In particular, XRCC1 was found to be augmented in cells either exposed to the drug combination or, albeit less markedly with the single agent at the highest concentration ( Figure 7 ).
Discussion
Methylation of O 6 -guanine has been considered as the main DNA lesion responsible for the cytotoxicity, mutagenicity and clastogenicity of methylating compounds in cells endowed with a functional MR. [29] [30] [31] Loss of MR function results not only in resistance to these agents and to other antineoplastic drugs, but is also associated with genetic instability. Thus, drug treatment itself might contribute in enriching genetically unstable cells, which rapidly acquire resistance to different antitumor agents.
Considering this scenario it was of interest to analyze the possible biological consequences of DNA damage other than that derived from the processing of The findings of the present study indicate that Me-Lex is cytotoxic for MR-deficient Jurkat and MT-1 leukemic cell lines and that PARP inhibition increases toxicity of the N 3 -methylating agent. The kinetics of appearance of the growth inhibitory effect was different from that resulting from the processing of O 6 -methylguanine in MR-proficient and OGAT-deficient cells. In fact, cytotoxicity induced by Me-Lex or by the drug combination was already evident 24 h after drug exposure. The killing effect, instead, deriving from O 6 -methylguanine appeared only at 48 h, 3 suggesting that permanent DNA damage would occur during the second cycle of DNA replication. In this case the replication fork encounters MR-induced strand interruptions and generates double-strand breaks. 2 In contrast, N 3 -MeA behaves as a replication blocking lesion, since the presence of the methyl group would alter the ability of the N 3 atom to stabilize the contact between DNA polymerase and DNA template. 15 This might explain the early appearance of cytotoxicity already evidenced within the first round of DNA replication.
The enhancing effect on Me-Lex cytotoxicity by PARP inhibitor was detectable in both lines although it was more evident at low drug concentrations that slightly affected cell growth at 24 h. This phenomenon might be due to the interruption of the BER repair process, after the removal of N 3 -MeA by MPG, leading to strand break generation. Similar enhancement of cytotoxicity was previously observed when leukemic cells were exposed to TZM combined with PARP inhibitors.
11 MR-deficient Jurkat cells express high levels of OGAT activity and are capable of repairing the low percent- age of O 6 -methylguanine generated by TZM. 32 Therefore, it is reasonable to hypothesize that PARP inhibition might impair the repair process of adducts generated by TZM at DNA site positions different from O 6 -guanine. It has been recently demonstrated that the presence of N 3 -MeA in the DNA is capable of inducing chromosome aberrations. 15 The clastogenic effect of N 3 -methylguanine would derive from a block of the replication fork, leaving short unreplicated regions which are prone to be converted into double-strand breaks. In the present study, we show that in human MR-deficient leukemic cells Me-Lex is capable of inducing clastogenic effects and that PARP inhibition enhanced the clastogenic potential of the agent. It seems reasonable to hypothesize that DNA strand interruptions, deriving from the incomplete repair of N 3 -MeA, might be converted in double-strand breaks that would give rise to chromosome aberrations.
Methylating triazene compounds have been previously shown to have clastogenic effects. 33, 34 In the case of TZM, OGAT-deficient cells, or cells pretreated with the OGAT inactivator O 6 -benzylguanine, are extremely sensitive to chromosome aberrations induced by treatment with methylating agents. 33 However, OGAT overexpression did not completely abolish the appearance of the clastogenic effect of methylating agents, thus indicating that DNA adducts different from O 6 -methylguanine might also contribute to the clastogenicity of these compounds. In our experimental model, where a MRdeficient cell line with high levels of OGAT activity (ie Jurkat) has been used, TZM alone did not induce a significant chromosome damage. Impairment of PARP activity increased this effect, suggesting that repair inhibition of DNA adducts different from O 6 -methylguanine is responsible for the clastogenic properties of TZM.
The apoptotic effect of Me-Lex alone was more pronounced in MT-1 than in Jurkat cells at 24 h (Figure 3) . Moreover, 3-AB significantly increased Me-Lex-induced apoptosis. Apoptosis Leukemia consequent to Me-Lex treatment along with interruption of BER process due to 3-AB-induced PARP inhibition, appears at an earlier time than that induced by the single agent. Consistent with this observation, fragmented nuclei were detected in Jurkat cells exposed to Me-Lex + 3-AB, but not to Me-Lex alone, as early as 6 h after treatment.
The present results clearly demonstrate that MT-1 cells were more susceptible to the cytotoxic effects of the N 3 -adenine methylating agent than Jurkat cells. Consistent with the direct role of N 3 -MeA in cytotoxicity, MT-1 cells expressed very low MPG activity in vitro, with respect to that of Jurkat cells. Moreover, it cannot be excluded that the activation of p53 by drug treatment might contribute to the marked apoptotic effect induced by the drug combination in MT-1 cells.
There are conflicting data regarding the role of MPG in resistance to alkylating agents. A clear relationship between MPG expression and resistance to these drugs has not been established. 35, 36 However, MPG-null ES murine cells were found to be more susceptible to Me-Lex and to methyl methanesulphonate, with respect to MPG-positive ES cells. 15, 16 In our model system, it is possible to hypothesize that the low levels of MPG activity present in MT-1 cells might be sufficient to repair the limited number of N 3 -methyl adducts induced by extremely low concentrations of Me-Lex. In this case the inhibition of the BER repair process, that follows the intervention of MPG could result in enhanced cytotoxicity. However, at high Me-Lex concentrations, the amount of active enzyme present in the cells becomes a rate limiting factor during the repair process. In these conditions, 3-ABinduced BER impairment appears to play a less important role.
Treatment with Me-Lex increased expression of XRCC1 transcript, which was more pronounced when Me-Lex was combined with 3-AB. XRCC1 is a member of the BER multiprotein complex which is capable of interacting with PARP, DNA polymerase ␤ and DNA ligase III. 37, 38 Increased XRCC1 expression was also detected in Jurkat cells treated with TZM and 3-AB, thus suggesting that unrepaired strand breaks might trigger the synthesis of this molecule. 11 The results obtained with Me-Lex alone or combined with 3-AB reinforce this hypothesis. The increase of XRCC1 transcript induced by MeLex alone, could be due to the renewed synthesis of the molecule consumed during the very active repair process.
In conclusion, the present work shows that Me-Lex induces cytotoxic, apoptotic and clastogenic effects in MR-deficient leukemic cells and that PARP inhibition potentiates cytotoxicity of this compound (see model illustrated in Figure 8 ). MRdeficient cells, which are resistant to the toxicity induced by O 6 -methylguanine, and possibly to various antineoplastic agents, remain susceptible to methylating agents capable of inducing N 3 -MeA adducts. In this case, high levels of MPG activity might induce resistance to these compounds, especially to those which generate low amounts of N 3 -MeA. However, association of the methylating agent to a PARP inhibitor would result in enhanced cytotoxicity in tumor cells with either high or low levels of MPG activity.
These results appear to be of potential clinical interest, because the blasts obtained from more than 90% of the patients with therapy-related leukemia present microsatellite instability, which is a hallmark of the genomic instability consequent to the loss of MR. 8 Therefore, therapeutic strategies based on the selective methylation of N 3 -adenine and/or inhibition of its repair might be of benefit for the treatment of MR-deficient tumors, which might be resistant to different antineoplastic agents.
